Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announces the completion of its previously announced merger with ARCA biopharma, Inc. The combined company will operate under the name Oruka Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Global Market today, September 3, 2024, under the ticker symbol “ORKA”.
Read the full article: Oruka Therapeutics Announces Closing of Merger with ARCA biopharma //
Source: https://www.globenewswire.com/news-release/2024/09/03/2939515/0/en/Oruka-Therapeutics-Announces-Closing-of-Merger-with-ARCA-biopharma-and-Previously-Announced-Private-Placement-of-275-Million.html